Merck’s Biotech Pipeline Gets A Boost From Two Acquisitions

Merck will buy the monoclonal antibody developer Abmaxis and yeast glycoengineering specialist GlycoFi.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet